INFI · Infinity Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $2.59M | $1.86M | $1.72M | $3.05M | $6.00M | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $32.41M | $31.65M | $26.76M | $27.12M | $19.76M | $20.83M |
| SG&A | $13.46M | $14.17M | $12.42M | $14.29M | $14.25M | $21.61M |
| Total Operating Expenses | $47.44M | $46.94M | $40.22M | $48.71M | $34.08M | $42.45M |
| D&A | $458.0K | $480.0K | $483.0K | $219.0K | $191.0K | $1.72M |
| Operating Income | ($44.84M) | ($45.08M) | ($38.50M) | ($45.66M) | ($11.93M) | ($36.45M) |
| Interest Expense | - | - | - | $2.56M | $93.0K | $1.01M |
| Income Tax | $0 | $0 | $0 | ($54.0K) | $0 | ($720.0K) |
| Net Income | ($44.37M) | ($45.26M) | ($40.49M) | ($47.06M) | ($11.25M) | ($41.83M) |
| EPS - Basic | ($0.50) | ($0.68) | - | - | - | - |
| EPS - Diluted | ($0.50) | ($0.68) | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $38.31M | $80.73M | $28.59M | $22.26M | $48.62M | $34.61M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $4.41M | $2.32M | $2.98M | $1.62M | $1.20M | $459.0K |
| Current Assets | $40.30M | $82.27M | $36.02M | $44.58M | $59.82M | $58.39M |
| Total Assets | $42.15M | $84.78M | $39.32M | $49.01M | $60.22M | $59.35M |
| Current Liabilities | $13.63M | $13.30M | $11.05M | $9.70M | $7.72M | $11.60M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $61.20M | $63.21M | $62.31M | $41.29M | $7.76M | $11.62M |
| Stockholders' Equity | ($19.05M) | $21.57M | ($22.99M) | $7.73M | $52.46M | $47.73M |
| Retained Earnings | ($855.95M) | ($811.58M) | ($766.32M) | ($725.83M) | ($678.77M) | ($667.52M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($42.43M) | ($40.62M) | ($35.74M) | ($41.53M) | ($36.71M) | ($36.71M) |
| Investing Cash Flow | ($55.0K) | $5.49M | $14.63M | ($12.24M) | ($4.28M) | ($4.28M) |
| Financing Cash Flow | $73.0K | $87.11M | $27.44M | $27.73M | ($146.0K) | $1.54M |
| CapEx | $17.0K | $11.0K | $43.0K | $2.33M | $0 | $43.0K |
| Free Cash Flow | ($42.45M) | ($40.63M) | ($35.78M) | ($43.86M) | ($36.71M) | ($36.75M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -1729.4% | -2426.4% | -2239.5% | -1497.7% | -198.8% | - |
| EBITDA margin | -1711.8% | -2400.6% | -2211.4% | -1490.5% | -195.6% | - |
| Net margin | -1711.1% | -2436.1% | -2355.6% | -1543.4% | -187.5% | - |
| Free cash flow margin | -1637.0% | -2186.7% | -2081.6% | -1438.4% | -611.9% | - |
| FCF / Net income | 0.96 | 0.90 | 0.88 | 0.93 | 3.26 | 0.88 |
| R&D / Revenue | 1249.9% | 1703.3% | 1556.8% | 889.3% | 329.3% | - |
| SG&A / Revenue | 519.2% | 762.9% | 722.4% | 468.6% | 237.5% | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -105.3% | -53.4% | -103.0% | -96.0% | -18.7% | -70.5% |
| Return on equity | 232.9% | -209.8% | 176.1% | -609.1% | -21.5% | -87.6% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.96 | 6.19 | 3.26 | 4.60 | 7.75 | 5.04 |
| Quick ratio | 2.96 | 6.19 | 3.26 | 4.60 | 7.75 | 5.04 |
| Cash ratio | 2.81 | 6.07 | 2.59 | 2.30 | 6.30 | 2.98 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | -17.8x | -128.3x | -36.1x |
| Equity multiplier | -2.21 | 3.93 | -1.71 | 6.34 | 1.15 | 1.24 |
| Liabilities / Assets | 1.45 | 0.75 | 1.58 | 0.84 | 0.13 | 0.20 |
| Efficiency | ||||||
| Asset turnover | 0.06 | 0.02 | 0.04 | 0.06 | 0.10 | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 39.6% | 8.1% | -43.6% | -49.2% | - | - |
| Revenue CAGR (3y) | -5.3% | -32.3% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 0.5% | -17.1% | 15.7% | -282.8% | 67.3% | -18.0% |
| Net income growth (YoY) | 2.0% | -11.8% | 14.0% | -318.2% | 73.1% | -39.0% |
| EPS growth (YoY) | 26.5% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -4.5% | -13.5% | 18.4% | -19.5% | 0.1% | 76.3% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | -85.3% | 9.9% | -42.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2020-12-31.
Product / service
$1.72M totalRoyalty$1.72M · 100.0%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-20.12
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing INFINITY PHARMACEUTICALS against the 5 most active filers in the same SIC group.